SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending as investors rally around the company's optical interconnect technology, with strong bullish sentiment following a CFO interview that dismissed short-seller concerns and highlighted ongoing engagement with hyperscalers. The community is actively discussing the stock's massive trading volume and the potential for a significant re-rating as the company moves toward scaling production and securing major purchase orders.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is experiencing significant upward momentum driven by intense retail interest and investor optimism regarding its gallium nitride (GaN) power chip technology, which is viewed as a critical component for future AI data center infrastructure. While bulls are encouraged by potential long-term partnerships and the company's role in next-gen power architectures, the community is actively debating whether this price action is a fundamental re-rating or a speculative short squeeze, with many participants warning of the company's current lack of profitability.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is seeing intense community engagement as investors speculate on a major trend reversal, fueled by positive housing market data and optimism regarding the company's integrated transaction model. Traders are actively discussing the stock's short-squeeze potential, citing significant short interest and technical breakouts that have many comparing its growth trajectory to other high-beta market plays.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is currently trending as the community debates the implications of the AACR poster presentation for SLS009 and monitors for major clinical catalysts, including the 80th survival event in the REGAL Phase 3 trial. Discussions remain intensely focused on the balance between institutional accumulation, potential buyout speculation, and concerns over corporate communication, with vocal debates between long-term investors and short sellers regarding the company's valuation and clinical progress.

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

The community is actively discussing ProShares Ultra Bloomberg Crude Oil (UCO) amidst extreme volatility in energy markets, fueled by fears of a supply crunch and a potential blockade in the Strait of Hormuz. Investors are intensely debating the impacts of geopolitical tensions on oil prices, with many questioning the efficacy of the ETF's leverage, while others argue that structural supply shortages could drive further upside.

Vertiv Holdings Co. engages in the design, manufacture, and service of critical digital infrastructure technology for data centers, communication networks, and commercial and industrial environments. The firm also offers power management products, switchgear and busbar products, thermal management products, integrated rack systems, modular solutions, and management systems for monitoring and controlling digital infrastructure. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa (EMEA). The Americas segment includes products and services sold for applications within the data center, communication networks and commercial and industrial markets in North America and Latin America. The Asia Pacific segment consists of products and services sold for applications within the data center, communication networks and commercial and industrial markets throughout Greater China, Asia, and India. The EMEA segment focuses on products and services sold for applications within the data center, communication networks, and commercial and industrial markets in Europe, Middle East, and Africa. The company was founded in 1946 and is headquartered in Westerville, OH.

Vertiv Holdings Co - Ordinary Shares - Class A

Vertiv Holdings Co

Vertiv Holdings is trending as investors react to a record 15 billion dollar backlog, robust Q4 growth, and anticipation of potential S&P 500 inclusion, driving massive institutional attention toward its AI data center infrastructure. The community is actively debating the stock's valuation after a significant year-to-date rally, with many traders monitoring for technical pullbacks or gap fills while others remain bullish on the long-term demand for its power and cooling solutions.

Vistra Corp. is a holding company, which engages in the provision of electricity and power generation. It operates through the following segments: Retail, Texas, East, West, and Asset Closure. The Retail segment includes sale of electricity and natural gas to residential, commercial, and industrial customers. The Texas and East segments are involved in electricity generation, wholesale energy sales and purchases, commodity risk management activities, fuel production and fuel logistics management. The West segment represents the company's electricity generation operations in CAISO. The Asset Closure segment refers to the decommissioning and reclamation of retired plants and mines. The company was founded in 1882 and is headquartered in Irving, TX.

Vistra Corp

Vistra Corp is trending as investors react to a significant 20-year power purchase agreement with Meta Platforms to supply nuclear energy to support data center growth, fueling bullish momentum. Despite recent market volatility and retail investor skepticism regarding valuation, the community is actively debating the stock's role as a cornerstone of AI infrastructure and debating entry points amidst broader energy sector rotations.

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Rigel Pharmaceuticals

Rigel Pharmaceuticals is trending as investors digest new clinical data from the ASH conference regarding its R289 IRAK1/4 inhibitor, which demonstrated red blood cell transfusion independence in heavily pre-treated MDS patients. The community is actively discussing the stock's strong commercial momentum and recent earnings performance, while speculating on the potential for strategic acquisitions or partnerships given the company's profitable status and pipeline progression.

Elevance Health, Inc. operates as a health company, which engages in improving lives and communities, and making healthcare simpler. It operates through the following segments: Health Benefits, CarelonRx, Carelon Services, and Corporate and Other. The Health Benefits segment offers a comprehensive suite of health plans and services to different customers. The CarelonRx segment markets and offers pharmacy services to affiliated health plan customers, as well as to external customers. The Carelon Services segment integrates physical, behavioral, pharmacy, and social services with the aim of delivering whole health affordably by offering a broad array of healthcare related services. The Corporate & Other segment includes businesses that do not individually meet the quantitative threshold for an operating segment. The company was founded in 1944 and is headquartered in Indianapolis, IN.

Elevance Health Inc

Elevance Health (ELV) is in the spotlight following strong quarterly results that surpassed analyst expectations on both earnings and revenue, even as the company navigates a challenging managed care environment. The market is actively weighing the company's raised full-year EPS guidance against broader sector concerns regarding Medicaid membership trends, regulatory scrutiny, and upcoming Medicare Advantage policy impacts.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending due to widespread speculation that a former company executive, Houman Hemmati, is a leading candidate for the FDA's top biologics regulator position. The community is actively discussing how this potential appointment, combined with the company's robust clinical trial data, could accelerate the approval process for their DMD therapy and trigger a significant upward valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What's Going On With WORK Medical Technology Group Stock Today?

Shares of WORK Medical are rising Monday after the company received manufacturing approval for one of its AI-powered products.read more...

<ul class="summary-bullets"><li>The system combines advanced imaging with AI software to analyze blood smears, conduct white blood cell counts, and assess red blood cells and platelets.</li><li>The company expects to begin manufacturing the analyzer in the first half of 2026.</li><li>Work Medical Technology had announced a 1-for-100 reverse stock split last week to comply with Nasdaq’s minimum price rule.</li></ul>Work Medical Technology Group (WOK) shares jumped more than 50% on Monday, before paring some of the gains, after the company secured Chinese regulatory approval to manufacture an AI-powered blood analysis device. At the same time, the stock also began trading on a reverse split basis.Work’s China-based subsidiary has secured regulatory approval from the Hunan Provincial Medical Products Administration to manufacture a Class II AI-powered medical device, called the AI-Automated Human Blood Cell Morphology Analyzer.The system combines advanced imaging hardware with AI software to analyze blood smears and perform white blood cell differential counts, while also assessing red blood cells and platelets. It will use deep-learning algorithms and a fully automated workflow to improve accuracy and consistency in laboratory testing. Work Medical expects to begin manufacturing the analyzer in the first half of 2026.Work’s CEO and chairman, Shuang Wu, expects that, with ongoing AI upgrades and deeper workflow integration, the device will become standard equipment across hospital hematology and oncology departments as well as primary-care labs.“We are optimistic about this product line’s growth and its revenue potential for the company,” Shuang Wu said.<h2 class="st-heading-2">1-For-100 Reverse Split</h2>Last week, <a href="https://stocktwits.com/symbol/WOK">Work Medical</a> said it would implement a 1-for-100 reverse stock split of its ordinary shares, effective on December 29. This resulted in every 100 shares of the company’s outstanding Class A and Class B ordinary shares being combined into one ordinary share. The move is aimed at maintaining compliance with Nasdaq’s minimum bid price requirement of $1.00.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits surrounding the stock shifted to ‘bullish’ from ‘bearish’ a day earlier.One user expects support at $3.87.<stembedurl>https://stocktwits.com/Zackpedia/message/640305180</stembedurl>Another user sees strong upside.<stembedurl>https://stocktwits.com/trading_momentum_x/message/640304021</stembedurl>Read Also: <a href="https://stocktwits.com/news-articles/markets/equity/silver-pullback-from-80-drives-hl-ag-paas-stock-lower/cL75u1sRExP">Silver’s $80 Breach Sparks Strong Pullback, Miners Feel The Heat: HL, AG, PAAS Stocks Drop Premarket</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A candlestick chart can be seen in a trading platform on a smartphone. Top U.S. firms announced record buybacks this year. (Photo by Silas Stein/picture alliance via Getty Images)

Why Did WOK Stock Surge Over 50% Today?

The company’s unit secured Chinese approval for an AI-powered blood analysis device, and the stock also began trading on a reverse-split basis from Monday.

Equity

WORK Medical Technology Group Ltd. engages in the development of health instruments. It manufactures and sells medical devices, including endotracheal tubes, laryngeal mask airways, heat and moisture exchanging filters, disposable breathing circuits, nebulizer kits, and yankauer suction sets. The company was founded on March 1, 2022 and is headquartered in Hangzhou, China.

WOK
Work Medical Technology Group Ltd

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest WOK News

WOKWork Medical Technology Group Ltd